Document:

Exhibit 4.1

 

CERTIFICATE OF DESIGNATIONS, PREFERENCES
AND RIGHTS OF THE

SERIES B CONVERTIBLE PREFERRED STOCK OF

BOSTON THERAPEUTICS, INC.

 

The undersigned, Conroy
Chi-Heng Cheng, President and Chief Executive Officer of Boston Therapeutics, Inc. (the “Corporation”), a corporation
organized and existing under the Delaware General Corporation Law (the “DGCL”), hereby does certify:

 

That pursuant to the
authority expressly conferred upon the Board of Directors of the Corporation by the Corporation’s Certificate of Incorporation,
as amended, and Section 141 of the DGCL, the Board of Directors on January 25, 2021, adopted the following resolution determining
it desirable and in the best interests of the Corporation and its shareholders for the Corporation to create a series of ONE MILLION
(1,000,000) shares of preferred stock designated as “Series B Convertible Preferred Stock”, none of which shares have
been issued.

 

RESOLVED, that
the Board of Directors designates the Series B Convertible Preferred Stock and the number of shares constituting such series, and
fixes the rights, powers, preferences, privileges and restrictions relating to such series in addition to any set forth in the
Articles of Incorporation as follows:

 

TERMS OF SERIES B CONVERTIBLE PREFERRED STOCK

 

1. Certain
Defined Terms. For purposes of this Certificate of Designations, the following terms shall have the following meanings:

 

(a) “1934
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. 

 

(b) “Affiliate”
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common
control with, such Person, it being understood for purposes of this definition that “control” of a Person means the
power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors
of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

(c) “Approval
Date” means the first Trading Day following the receipt of Shareholder Approval.

 

(d) “Certificate
of Designations” means this Certificate of Designations, Preferences and Rights of the Series B Convertible Preferred
Stock of the Corporation. 

 

(e) “Common
Stock” means (i) the Corporation’s shares of common stock, $0.001 par value per share, and (ii) any capital
stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common
stock.

 

(f) “Conversion
Date” shall have the meaning given to it in Section 5 hereto.

 

(g) “Conversion
Notice” shall have the meaning given to it in Section 5 hereto.

 

(h) “Conversion
Rate” shall equal 1,000 shares of Common Stock to each share of Series B Preferred Stock, subject to adjustment for stock
splits, stock dividends, recapitalizations, reorganizations, reclassifications, combinations, subdivisions or other similar events
occurring after the date which the Series C Preferred Stock are issued.

 

    

     

    

 

(i)   [Reserved]

 

(j) “Conversion
Shares” shall have the meaning given to it in Section 5 hereto.

 

(k) “Corporate
Event” shall have the meaning given to it in Section 6 hereto. 

 

(l) “Corporation”
shall have the meaning given to it in the preamble hereto. 

 

(m) “Delivery
Notice” shall have the meaning given to it in Section 5 hereto.

 

(n)
“Distributions” shall have the meaning given to it in Section 10 hereto.

 

(o)
“DTC” shall have the meaning given to it in Section 5 hereto.

 

(p) “Fundamental
Transaction” shall have the meaning given to it in Section 6. 

 

(q) “Holder”
or “Holders” means a holder of Series B Preferred Stock.

 

(r) “Junior
Stock” shall have the meaning given to it in Section 3 hereto.

 

(s) “Liquidation
Event” means, whether in a single transaction or series of transactions, the voluntary or involuntary liquidation, dissolution
or winding up of the Corporation or such Subsidiaries the assets of which constitute all or substantially all of the assets of
the business of the Corporation and its Subsidiaries, taken as a whole.

 

(t) “Liquidation
Funds” shall have the meaning given to it in Section 9 hereto.

 

(u) “DGCL”
shall have the meaning given to it in the preamble hereto.

 

(v)  [Reserved]

 

(w) [Reserved]

 

(x) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity or a government or any department or agency thereof.

 

(y) “Principal
Market” means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market,
the Nasdaq Capital Market, OTCPink, OTCQB, or OTCQX and any successor markets thereto.

 

    2

     

    

 

(z) “Restricted
Shares” means shares of the Corporation’s Common Stock which are restricted from being transferred by the Holder
thereof unless the transfer is effected in compliance with the Securities Act and applicable state securities laws (including investment
suitability standards, which shares shall bear the following restrictive legend (or one substantially similar)): “The
securities represented by this certificate have not been registered under the Securities Act of 1933 or any state securities act.
The securities have been acquired for investment and may not be sold, transferred, pledged or hypothecated unless (i) they shall
have been registered under the Securities Act of 1933 and any applicable state securities act, or (ii) the corporation shall have
been furnished with an opinion of counsel, satisfactory to counsel for the corporation, that registration is not required under
any such acts.”

 

(aa)
“SEC” means the Securities and Exchange Commission or the successor thereto.

 

(bb) “Senior
Preferred Stock” shall have the meaning given to it in Section 3 hereto. 

 

(cc) “Series
B Preferred Stock” shall have the meaning given to it in Section 2 hereto.

 

(dd) “Series
B Certificates” shall have the meaning given to it in Section 5 hereto.

 

(ee) “Share
Delivery Deadline” shall have the meaning given to it in Section 5 hereto.

 

(ff) “Shareholder
Approval” shall mean the approval of an amendment to the Corporation’s Certificate of Incorporation, as amended,
to implement a one-for-180 reverse stock split of the Corporation’s capital stock by a majority of the votes entitled to
be cast thereon, whether presented at a special or annual meeting of shareholders of the Corporation or by written consent of the
shareholders and the subsequent filing of such amendment with the Secretary of State of the State of Delaware.

 

(gg) “Stated
Value” shall mean $1.00 per share, subject to adjustment for stock splits, stock dividends, recapitalizations, reorganizations,
reclassifications, combinations, subdivisions or other similar events occurring after the date which the Series B Preferred Stock
are issued.

 

(hh) “Subsidiary”
when used with respect to any Person, means any corporation or other organization, whether incorporated or unincorporated, of which
(A) at least a majority of the securities or other interests having by their terms ordinary voting power to elect a majority
of the board of directors or others performing similar functions with respect to such corporation or other organization is directly
or indirectly owned or controlled by such Person (through ownership of securities, by contract or otherwise) or (B) such Person
or any subsidiary of such Person is a general partner of any general partnership or a manager of any limited liability company.

 

(ii)
“Trading Day” means any day on which the Common Stock is eligible to be traded
on the Principal Market or securities market on which the Common Stock is then traded, provided that “Trading Day”
shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or
any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such
exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending
at 4:00 p.m., Eastern time) unless such day is otherwise designated as a Trading Day in writing by the Holder.

 

(jj) “Transfer
Agent” shall have the meaning given to it in Section 5 hereto.

 

    3

     

    

 

2. Designation
and Number of Shares. There shall hereby be created and established a series of preferred stock of the Corporation designated
as “Series B Convertible Preferred Stock” (the “Series B Preferred Stock”). The authorized number
of Series B Preferred Stock shall be One Million (1,000,000) shares. Each share of Series B Preferred Stock shall have a par value
of $0.001.

 

3. Ranking.
The Series C Preferred Stock shall be senior in rank to the Series B Preferred Stock in respect of the preferences as to dividends,
distributions and payments upon the liquidation, dissolution and winding up of the Corporation. All other shares of capital stock
of the Corporation shall be junior in rank to all Series B Preferred Stock with respect to the preferences as to dividends, distributions
and payments upon the liquidation, dissolution and winding up of the Corporation (such junior stock is referred to herein collectively
as “Junior Stock”). The rights of all such Junior Stock shall be subject to the rights, powers, preferences
and privileges of the Series B Preferred Stock. Without limiting any other provision of this Certificate of Designations, the Corporation
shall not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series
B Preferred Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and
winding up of the Corporation other than the Series C Preferred Stock (collectively, the “Senior Preferred Stock”)
or (ii) any Junior Stock having a maturity date (or any other date requiring redemption or repayment of such shares of Junior Stock)
that is prior to the date no Series B Preferred Stock remain outstanding. 

 

4. Dividends
and Distributions. Each Holder of Series B Preferred Stock shall be entitled to receive dividends or distributions on each
share of Series B Preferred Stock on an “as converted” into Common Stock basis as provided in Section 5 hereof when
and if dividends are declared on the Common Stock by the Board of Directors. Dividends shall be paid in cash or property, as determined
by the Board of Directors.

 

5. Conversion.

 

(a) Upon
the terms and in the manner set forth in this Section 5, each outstanding share of the Series B Preferred Stock Preferred Stock
will automatically convert on the Approval Date (such date, the “Conversion Date”) into a number of fully-paid
and non-assessable shares of Common Stock determined by multiplying such share of Series B Preferred Stock Preferred Stock by the
Conversion Rate (such shares of Common Stock issuable upon Conversion, the “Conversion Shares”).

 

(b) As
promptly as practicable after the Conversion Date, the Corporation shall provide notice of the conversion (the “Conversion
Notice”) to each Holder stating the Conversion Date, the number of shares of Common Stock to be issued upon conversion
of each share of Series B Preferred Stock held of record by such Holder and subject to conversion and the place or places where
certificates representing shares of Series B Preferred Stock are to be surrendered for issuance of shares of Common Stock if such
shares are not held in book-entry. As promptly as practicable after receipt of the Conversion Notice from the Corporation, (i)
if any Holder holds its shares of Series B Preferred Stock in certificated form, then such the Holder shall surrender to a nationally
recognized overnight delivery service for delivery to the Corporation the original certificates representing the Series B Preferred
Stock (the “Series B Certificates”) so converted as aforesaid (or an indemnification undertaking with respect
to the Series B Preferred Stock in the case of its loss, theft or destruction as contemplated by Section 12) and (ii) all Holders
must send a copy of the executed delivery notice in the form attached hereto as Exhibit I (the “Delivery Notice”).
On or before the first Trading Day following the date of receipt of a Series B Certificate, if any, and Delivery Notice from a
Holder, the Corporation shall transmit by electronic mail an acknowledgment of confirmation, in the form attached hereto as Exhibit
II, of receipt of such Series B Certificate, if any, and Delivery Notice to such Holder and the Corporation’s transfer
agent (the “Transfer Agent”), which confirmation shall constitute an instruction to the Transfer Agent to issue
the Conversion Shares such Holder is entitled. On or before the third Trading Day following the date of receipt of a Delivery Notice
(or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a
trade initiated on the applicable Conversion Date of such Conversion Shares) (the “Share Delivery Deadline”),
the Corporation shall (1) provided that the Transfer Agent is participating in The Depository Trust Corporation’s (“DTC”)
Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which such Holder shall be
entitled to such Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system,
or (2) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via
reputable overnight courier) to the address as specified in such Conversion Notice, a certificate, registered in the name of such
Holder or its designee, for the number of shares of Common Stock to which such Holder shall be entitled. Unless the Conversion
Shares are covered by a valid and effective registration under the Securities Act, such shares shall be issued as Restricted Shares.
Notwithstanding the above, if requested by the Holder, the Corporation shall cause its counsel at the Corporation’s expense
to issue any necessary legal opinion (to the extent lawful) in order to permit sales of the Common Stock pursuant to Rule 144 under
the Securities Act or under another applicable exemption from the registration requirements; provided that (i) an exemption under
Rule 144 under the Securities Act or another applicable exemption from the registration requirements is available with respect
to such shares, and (ii) the Holder provides the Corporation and the legal counsel providing the necessary opinion with such representations
and other related information reasonably requested in order for such legal counsel to issue the legal opinion.

 

    4

     

    

 

(c) The
Holder shall be deemed to have become a shareholder of record on the Conversion Date. Immediately upon conversion, the rights of
the Holders as such with respect to the Series B Preferred Stock so converted shall cease and the persons entitled to receive the
shares of Common Stock upon the conversion of such shares of Series B Preferred Stock shall be treated for all purposes as having
become the record and beneficial owners of such shares of Common Stock. Nothwithstanding the foregoing, any shares of Preferred
Stock not converted on the Conversion Date as a result of the application of the provisions of subsection (f) below, shall automatically
be converted on the sixty-first day of the Conversion Date.

 

(d) If
any Conversion of Series B Preferred Stock would result in the issuance of a fractional share of Common Stock to any Holder, such
fractional share shall be payable in cash based upon the market value of the Common Stock on the Principal Market prior to the
date of Conversion and the number of shares of Common Stock issuable upon Conversion of the Series B Preferred Stock shall be the
next lower whole number of shares. If the Corporation elects not to, or is unable to, make such a cash payment, the Holder shall
be entitled to receive, in lieu of the final fraction of a share, one whole share of Common Stock.

 

(e) The
issuance of certificates for shares of Common Stock upon Conversion of the Series pursuant to Section 5 shall be made without payment
of additional consideration by, or other charge, cost or tax to, the Holder in respect thereof.

 

(f) Notwithstanding
the foregoing, the Corporation shall not effect any conversion of the Preferred Stock, and the Holder shall not have the right
to convert any portion of the Preferred Stock to the extent that after giving effect to such conversion, the Holder (together with
the Holder’s affiliates), as set forth on the applicable Notice of Conversion, would beneficially own in excess of 4.9% of
the number of shares of the Common Stock Outstanding immediately after giving effect to such conversion.  Beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act. To the extent that the limitation contained in this Section
applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by the Holder together
with any affiliates) and of which shares of Preferred Stock is convertible shall be in the sole discretion of such Holder, and
the submission of a Notice of Conversion shall be deemed to be such Holder’s determination of whether the shares of Preferred
Stock may be converted (in relation to other securities owned by such Holder) and which shares of the Preferred Stock is convertible,
in each case subject to such aggregate percentage limitations. To ensure compliance with this restriction, the Holder will be deemed
to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the
restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such
determination. For purposes of this Section 4(a)(iii), in determining the number of outstanding shares of Common Stock, the Holder
may rely on the number of outstanding shares of Common Stock as reflected in the most recent of the following: (A) the Corporation’s
most recent Form 10-Q or Form 10-K, as the case may be, (B) a more recent public announcement by the Corporation or (C) any other
notice by the Corporation or the Corporation’s transfer agent setting forth the number of shares of Common Stock Outstanding. 
Upon the written or oral request of the Holder, the Corporation shall within two Trading Days confirm orally and in writing to
the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred
Stock, by the Holder or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported.
This restriction may not be waived. 

 

    5

     

    

 

6. Rights
Upon Corporate Events. In addition to and not in substitution for any other rights hereunder, prior to the consummation of
any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets
with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Corporation shall make
appropriate provision to insure that each Holder will thereafter have the right to receive upon a conversion of all the Series
B Preferred Stock held by such Holder (i) in addition to the shares of Common Stock receivable upon such conversion, such securities
or other assets to which such Holder would have been entitled with respect to such shares of Common Stock had such shares of Common
Stock been held by such Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions
on the convertibility of the Series B Preferred Stock contained in this Certificate of Designations) or (ii) in lieu of the shares
of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of
Common Stock in connection with the consummation of such Corporate Event in such amounts as such Holder would have been entitled
to receive had the Series B Preferred Stock held by such Holder initially been issued with conversion rights for the form of such
consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion
Rate. The provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions
of this Section 6 shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations
on the conversion of the Series B Preferred Stock contained in this Certificate of Designations. “Fundamental Transaction”
means the occurrence of the Corporation (i) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in
one or more related transactions, (A) consolidating or merging with or into (whether or not the Corporation is the surviving corporation)
another Person, (B) selling, assigning, transferring, conveying or otherwise disposing of all or substantially all of the properties
or assets of the Corporation or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to
one or more Persons, (C) making, or allowing one or more Persons to make, or allowing the Corporation to be subject to or have
its Common Stock be subject to or party to one or more Persons making, a purchase, tender or exchange offer that is accepted by
the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock
calculated as if any shares of Common Stock held by all Persons making or party to, or Affiliated with any Persons making or party
to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Persons
making or party to, or Affiliated with any Person making or party to, such purchase, tender or exchange offer, become collectively
the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock,
(D) consummating a stock or share purchase agreement or other business combination (including a reorganization, recapitalization,
spin-off or scheme of arrangement) with one or more Persons whereby all such Persons, individually or in the aggregate, acquire,
either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated
as if any shares of Common Stock held by all the Persons making or party to, or Affiliated with any Persons making or party to,
such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock
such that the Persons become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of
the outstanding shares of Common Stock, or (E) reorganize, recapitalize or reclassify its Common Stock.

 

    6

     

    

 

7. Noncircumvention.
The Corporation hereby covenants and agrees that the Corporation will not, by amendment of its Articles of Incorporation, Bylaws
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of
securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Certificate
of Designations, and will at all times in good faith carry out all the provisions of this Certificate of Designations and take
all action as may be required to protect the rights of the Holders. Without limiting the generality of the foregoing or any other
provision of this Certificate of Designations, the Corporation (a) shall not increase the par value of any shares of Common Stock
receivable upon the conversion of any Series B Preferred Stock above the Conversion Rate then in effect and (b) shall take all
such actions as may be necessary or appropriate in order that the Corporation may validly and legally issue fully paid and non-assessable
shares of Common Stock upon the conversion of Series B Preferred Stock.

 

8. Voting
Rights. The Series B Preferred Stock shall not have voting rights, provided, however, effective January 1, 2022, each Holder
shall be entitled to the whole number of votes equal to the number of shares of Common Stock into which such holder’s Series
B Preferred Stock would be convertible on the record date for the vote or consent of stockholders, and shall otherwise have
voting rights and powers equal to the voting rights and powers of the Common Stock. To the extent that under the DGCL the vote
of the holders of the Series B Preferred Stock, voting separately as a class or series as applicable, is required to authorize
a given action of the Corporation, the affirmative vote or consent of the holders of a majority of the shares of the outstanding
Series B Preferred Stock, shall constitute the approval of such action by both the class or the series, as applicable (except
as otherwise may be required under the DGCL). Holders of the Series B Preferred Stock shall be entitled to written notice
of all stockholder meetings or written consents (and copies of proxy materials and other information sent to stockholders) with
respect to which they would be entitled by vote, which notice would be provided pursuant to the Corporation’s Bylaws and
the DGCL.

 

9. Liquidation,
Dissolution, Winding-Up. In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets
of the Corporation, whether from capital or from earnings available for distribution to its stockholders (the “Liquidation
Funds”), before any amount shall be paid to the holders of any of shares of Junior Stock but following the payment to
any Senior Preferred Stock an amount per share of Series B Preferred Stock equal to the greater of (A) the Stated Value of such
Series B Preferred Stock on the date of such payment and (B) the amount per share such Holder would receive if such Holder converted
such Series B Preferred Stock into Common Stock immediately prior to the date of such payment, provided that if the Liquidation
Funds are insufficient to pay the full amount due to the Holders, then each Holder shall receive a percentage of the Liquidation
Funds equal to the full amount of Liquidation Funds payable to such Holder as a liquidation preference, in accordance with their
respective certificate of designations (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all
holders of Series B Preferred Stock. To the extent necessary, the Corporation shall cause such actions to be taken by each of its
Subsidiaries so as to enable, to the maximum extent permitted by law, the proceeds of a Liquidation Event to be distributed to
the Holders in accordance with this Section 9. All the preferential amounts to be paid to the Holders under this Section shall
be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any
Liquidation Funds of the Corporation to the holders of shares of Junior Stock in connection with a Liquidation Event as to which
this Section 11 applies.

 

    7

     

    

 

10. Distribution
of Assets. If the Corporation shall declare or make any dividend or other distributions of its assets (or rights to acquire
its assets) to any or all holders of shares of Common Stock, by way of return of capital or otherwise (including any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (the “Distributions”), then each Holder, as holders of Series
B Preferred Stock, will be entitled to such Distributions as if such Holder had held the number of shares of Common Stock acquirable
upon complete conversion of the Series B Preferred Stock immediately prior to the date on which a record is taken for such Distribution
or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for such Distributions.

 

11. Transfer
of Series. A Holder may transfer some or all of its Series B Preferred Stock without the consent of the Corporation, subject
to compliance with Section 5 of the Securities Act of 1933.

 

12. Form
of Security. The Series B Preferred Stock shall be issued as book-entry securities directly registered in the stockholder’s
name on the Corporation’s books and records or, if requested by any holder of the Series B Preferred Stock, such holder’s
shares may be issued in certificated form.

 

13. Remedies,
Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Certificate of Designations
shall be cumulative and in addition to all other remedies available under this Certificate of Designations, at law or in equity
(including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit any Holder’s
right to pursue actual and consequential damages for any failure by the Corporation to comply with the terms of this Certificate
of Designations. The Corporation covenants to each Holder that there shall be no characterization concerning this instrument other
than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and
the computation thereof) shall be the amounts to be received by a Holder and shall not, except as expressly provided herein, be
subject to any other obligation of the Corporation (or the performance thereof). The Corporation acknowledges that a breach by
it of its obligations hereunder will cause irreparable harm to the Holders and that the remedy at law for any such breach may be
inadequate. The Corporation therefore agrees that, in the event of any such breach or threatened breach, each Holder shall be entitled,
in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or
other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages
and without posting a bond or other security. The Corporation shall provide all information and documentation to a Holder that
is requested by such Holder to enable such Holder to confirm the Corporation’s compliance with the terms and conditions of
this Certificate of Designations.

 

14. Attorneys
Fees. If (i) any shares of Series B Preferred Stock are placed in the hands of an attorney to enforce the provisions of this
Certificate of Designations or (ii) there occurs any bankruptcy, reorganization, receivership of the Corporation or other proceedings
affecting Corporation creditors’ rights and involving a claim under this Certificate of Designations, then the Corporation
shall pay the costs incurred by such Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including attorneys’ fees and disbursements. 

 

    8

     

    

 

15. Construction;
Headings. This Certificate of Designations shall be deemed to be jointly drafted by the Corporation and the Holders and shall
not be construed against any such Person as the drafter hereof. The headings of this Certificate of Designations are for convenience
of reference and shall not form part of, or affect the interpretation of, this Certificate of Designations. Unless the context
clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural
forms thereof. The terms “including,” “includes,” “include” and words of like import shall
be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,”
“hereof” and words of like import refer to this entire Certificate of Designations instead of just the provision in
which they are found. Unless expressly indicated otherwise, all section references are to sections of this Certificate of Designations.

 

16. Failure
or Indulgence Not Waiver. No failure or delay on the part of a Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other
or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and
signed by an authorized representative of the waiving party. This Certificate of Designations shall be deemed to be jointly drafted
by the Corporation and all Holders and shall not be construed against any Person as the drafter hereof. 

 

17. Governing
Law; Exclusive Jurisdiction. This Certificate of Designations shall be construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Certificate of Designations shall be governed by,
the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than
the State of Delaware. Except as otherwise required by this Certificate of Designations, the Corporation hereby irrevocably submits
to the exclusive jurisdiction of the Court of Chancery in the State of Delaware, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing
contained herein shall be deemed or operate to preclude any Holder from bringing suit or taking other legal action against the
Corporation in any other jurisdiction to collect on the Corporation’s obligations to such Holder, to realize on any collateral
or any other security for such obligations, or to enforce a judgment or other court ruling in favor of such Holder. The Corporation
hereby irrevocably waives any right it may have to, and agrees not to request, a jury trial for the adjudication of any dispute
hereunder or in connection with or arising out of this Certificate of Designations or any transaction contemplated hereby.

 

18. Severability.
If any provision of this Certificate of Designations is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Certificate of Designations so long as this Certificate
of Designations as so modified continues to express, without material change, the original intentions of the parties as to the
subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially
impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would
otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid
or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s).

 

    9

     

    

 

19. Stockholder
Matters; Amendment. 

 

(a) Stockholder
Matters. Any stockholder action, approval or consent required, desired or otherwise sought by the Corporation pursuant to the
DGCL, the Certificate of Incorporation, this Certificate of Designations or otherwise with respect to the issuance of Series B
Preferred Stock may be effected by written consent of the Corporation’s stockholders or at a duly called meeting of the
Corporation’s stockholders, all in accordance with the applicable rules and regulations of the DGCL. This provision is intended
to comply with the applicable sections of the DGCL permitting stockholder action, approval and consent affected by written consent
in lieu of a meeting.

 

(b) Amendment.
This Certificate of Designations or any provision hereof (other than Section 5(d)) may be modified or amended or the provisions
hereof waived with the written consent of the Corporation and the Holders of a majority of the Series B Preferred Stock
currently outstanding. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving
party.

 

* * * * *

    10

     

    

 

IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Designations of Series B Convertible Preferred Stock of Boston Therapeutics, Inc.
to be signed by its Chief Executive Officer on this 25th day of January, 2021.

 

	 	BOSTON THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ Conroy
    Cheng
	 	Name:	Conroy Cheng
	 	Title: 	CEO

 

    

     

    

 

EXHIBIT I

 

BOSTON THERAPEUTICS, INC.

DELIVERY NOTICE

 

Reference is made to
the Certificate of Designations, Preferences and Rights of the Series ______ Convertible Preferred Stock of Boston Therapeutics,
Inc. (the “Certificate of Designations”). In accordance with and pursuant to the Conversion Notice the Holder
received from the Corporation, the Holder hereby directs the Corporation to:

 

Please issue the Common Stock into which
the applicable Series ______ are being converted to Holder, or for its benefit, as follows:

 

		☐	Check here if requesting delivery as a certificate to the following
name and to the following address:

 

	 	Issue to:	 
	 	 	 
	 	 	 

 

		☐	Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:

 

	 	DTC Participant:	 
	 	DTC Number:	 
	 	Account Number:  	 

 

Date: _____________ __, 2020

 

	 	 
	Name of Registered Holder

 

	By:	 	 
	 	Name: 	 
	 	Title:	 

 

Tax ID:_____________________

Facsimile:___________________

E-mail Address: ___________________

 

    

     

    

 

EXHIBIT II

 

ACKNOWLEDGMENT

 

The Corporation hereby
acknowledges this Delivery Notice and hereby directs ____________ to issue _________________ shares of Common Stock in accordance
with the Transfer Agent Instructions dated _____________, 20__ from the Corporation and acknowledged and agreed to by West Coast
Stock Transfer.

 

	 	BOSTON THERAPEUTICS, INC.
	 	 	 
	 	By:	                
	 	 	Name:
	 	 	Title:Exhibit 10.1

 

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT
(the “Agreement”) is made as of the ___ day of _____ 2021, by and between, Boston Therapeutics, Inc., a Delaware
corporation (the “Company”), and ____________ (the “Holder”).

 

WHEREAS, the Holder
holds _______________ (collectively, the “Securities”).

 

WHEREAS, subject to
the satisfaction of the conditions set forth herein, the Company and the Holder desire to enter into a transaction wherein the
Company shall issue the Holder ________ shares of common stock, $0.001 par value per share, of the Company (the “Shares”),
in exchange for the Securities.

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1. Exchange.
The closing of the Exchange (the “Closing”) will occur on or before ________, 2021 (or such later date as the
parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date, the “Closing
Date”). On the Closing Date, subject to the terms and conditions of this Agreement, the Holder shall, and the Company
shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the “Securities Act”), exchange the Securities
for the Shares. At the Closing, the following transactions shall occur (such transactions in this Section 1, the “Exchange”):

 

1.1. Delivery
of Securities. On the Closing Date, the Company shall issue the Shares to the Holder (or its designees); provided that the
Holder has complied with its obligations in this Section 1. Promptly after the Closing Date, the Company shall deliver
a certificate evidencing the Shares to the Holder. On the Closing Date, the Holder shall be deemed for all corporate purposes to
have become the holder of record of the Shares.

 

1.2. No Rights
Following Exchange. Upon receipt of the Shares in accordance with Section 1.1, the Holder’s rights under
the Securities shall be extinguished. In consideration for the issuance of the Shares, the Holder hereby irrevocably waives any
obligations of the Company under the Securities or any purchase agreement or any other document executed in connection with the
issuance of the Securities.

 

1.3. Further
Assurances. The Company and the Holder shall execute and/or deliver such other documents and agreements as are customary and
reasonably necessary to effectuate the Exchange.

 

1.4. Termination
Before Closing. If the Closing has not occurred on or prior to February 28, 2021, the Holder shall have the right, by delivery
of written notice to the Company to terminate this Agreement (such date, the “Termination Date”).

 

1.5. Representations
and Warranties True at Closing. It shall be a condition to the obligation of the Holder on the one hand and Company on the
other hand, to consummate the Exchange contemplated hereunder that the other party’s representations and warranties contained
herein are true and correct on the Closing Date with the same effect as though made on such date, unless waived in writing by the
party to whom such representations and warranties are made.

 

1.6. Deliveries.
At or before the Closing, the Holder shall deliver or cause to be delivered to the Company, (i) the Securities held by such Holder
free and clear of all liens, encumbrances, security interests, options or other purchase rights, equities, charges, claims, pledges,
defects of title or other restrictions of any kind (other than federal and state securities laws) (ii) the executed Agreement and
(iii) other items required to effectuate the Exchange.

 

2. Representations
and Warranties of the Company. The Company hereby represents and warrants to the Holder that:

 

2.1. Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware. The Company is duly qualified to transact business and is in good standing in each jurisdiction
in which the failure to so qualify would have a Material Adverse Effect (as defined below) on its business or properties. As used
in this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets,
liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its Subsidiaries,
if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange (as defined below) or by
the agreements and instruments to be entered into (or entered into) in connection herewith or therewith, or on the authority or
ability of the Company to perform its obligations under this Agreement or the Exchange.

 

    1

     

    

 

2.2. Authorization.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement and the other Exchange and the performance of all obligations of the Company hereunder and thereunder,
and the authorization of the Exchange, the issuance of the Shares have been taken on or prior to the date hereof.

  

2.3. Valid Issuance
of the Shares. The Shares when issued and delivered in accordance with the terms of this Agreement, for the consideration expressed
herein for the consideration expressed herein, will be duly and validly issued, fully paid and non-assessable.

 

2.4. Validity;
Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Company
and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with
their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement
of applicable creditors’ rights and remedies. The execution, delivery and performance by the Company of this Agreement and
the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational
documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company is a party or by which it is bound, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities or “Blue Sky” laws) applicable to the
Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Effect.

 

3. Representations
and Warranties of the Holder. The Holder hereby represents, warrants and covenants that:

 

3.1. Authorization.
The Holder has full power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate the
transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery of this Agreement,
the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.

 

3.2. Exchange
Only. The Holder is a current holder of Securities and has not provided any consideration to the Company for the Shares received
in the Exchange other than the Securities. The Holder understands that: (i) the Securities have not been and are not being registered
under the Securities Act or any state securities laws, and the Shares issued in the Exchange may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder, (B) pursuant to Rule 144, or (C) pursuant to another exemption
from registration under the Securities Act, including but not limited to Section 3(a)(9) thereunder.

 

3.3. No Governmental
Review. The Holder understands that no United States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in the Shares
nor have such authorities passed upon or endorsed the merits of the offering of the Shares.

  

3.4. Validity;
Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder
and shall constitute the legal, valid and binding obligations of the Holder enforceable against the Holder in accordance with their
respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.

 

    2

     

    

 

3.5. Ownership
of Securities. The Holder owns and holds, beneficially and of record, the entire right, title, and interest in and to the Securities
free and clear of all rights and liens (other than pledges or security interests (x) arising by operation of applicable securities
laws and (y) that the Holder may have created in favor of a prime broker under and in accordance with its prime brokerage agreement
with such broker). The Holder has full power and authority to transfer and dispose of the Securities to the Company free and clear
of any right or lien. Other than the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal,
or other right of any Person to acquire all or any part of the Securities.

 

4. Additional
Covenants.

 

4.1. Holding
Period. For the purposes of Rule 144 of the Securities Act, the Company acknowledges that (i) the holding period of the Securities
may be tacked onto the holding period of the Shares as long as no payment is made in connection with any conversion, and (ii) the
holding period of the Shares may be tacked onto the holding period of the Common Stock, and the Company agrees not to take a position
contrary to this Section 4.1.

 

4.2. Blue Sky.
The Company shall make all filings and reports relating to the Exchange required under applicable securities or “Blue Sky”
laws of the states of the United States following the date hereof, if any.

 

4.3. Issuance
of Unrestricted Common Stock. The Company agrees to take all actions, including, without limitation, the issuance by its legal
counsel, or any legal counsel reasonably acceptable to the Company, of any legal opinions, to issue unrestricted Shares in accordance
with Rule 144 in the connection of any sale of the Shares; provided that the Holder provides customary representation letters and
all other such documentation as required by counsel to the Company to issue a legal opinion.

 

4.4 Lock up; Leak
Out.  For a period
of twelve months from the Closing, the Holder shall not sell, sell short, grant an option to buy, or otherwise dispose of any
of the Shares; provided, however, notwithstanding the restrictions set forth herein, commencing on the
six (6) month anniversary of the Closing, the Holder may sell up to ten (10%) percent of the Shares per month.

 

5. Miscellaneous

 

5.1. Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express
or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

  

5.2. Governing
Law; Exclusive Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of
any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the
state or federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT
OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    3

     

    

 

5.3. Notices.
All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar overnight next business day delivery, or by email followed
by overnight next business day delivery, to the address as provided for on the signature page to this Agreement.

 

5.4. Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the Holder.

 

5.5. Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms so long as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s)
in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close
as possible to that of the prohibited, invalid or unenforceable provision(s).

 

5.6. Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

5.7. Survival. Section
4 and 5 of this Agreement shall survive the Closing and delivery of the Shares.

 

[SIGNATURES ON THE FOLLOWING PAGE]

  

    4

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	BOSTON THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	Conroy Chi-Heng Cheng
	 	Title:	Chief Executive Officer
	 	 
	 	Address for Notices:
	 	 
	 	
        354 Merrimack Street #4

        Lawrence, MA 01843

        Email:

 

    5

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	HOLDER:

 

	 	[     ]	 
	 	 	 
	 	By:	 
	 	
        Name:

        Title:

        
	 

 

	 	Address for Notices:
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	 
	 	 	 
	 	Email:	 	 
	 	 	 	 
	 	SSN#:	 	 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]